DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Depressed woman with head in hands

UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety

The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...

Mining the Microbiome: Microbiome startups are proliferating, exploring new markets, and colonizing diverse therapeutic...

It would be hard to find an area of health where the microbiome has not been implicated as a major player. The microbiome is...

PerkinElmer Genomics, U. of Iowa Develop FSHD Assay Based on Bionano’s Saphyr

Bionano Genomics announced at the American Society of Human Genetics (ASHG) annual meeting in Houston that PerkinElmer Genomics and the University of Iowa have...

Small Sequencer Developer GenapSys Completes $90M Series C Financing

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
The American Association of Clinical Urologists (AACU) has issued a position statement encouraging the use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients. [Ji-Xin Cheng

Clinical Urologists Group Supports Genomic Testing for Prostate Cancer

AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients

10x Genomics Graduates from ‘Super Success’ to $100M IPO

10x Genomics has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities...

Promega to Develop MSI Technology as CDx to Merck’s Keytruda

Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.

FoundationOne CDx Approved as Companion Diagnostic to Lynparza in Ovarian Cancer

The FDA has approved an expanded indication for Foundation Medicine’s FoundationOne®CDx, authorizing the test as a companion diagnostic for the AstraZeneca/Merck & Co. co-developed...

CRISPR Detectives: Startups seek to expand access to diagnostics with inexpensive CRISPR-based tests

CRISPR-Cas9 is best known for its powerful ability to make double-stranded breaks in DNA, allowing scientists to delete and edit genes with relative ease....
Scroll Up